Research Article

Functional Status of Pancreatic α and β Cells in Type 2 Diabetes Mellitus Patients with Different Plasma Triglyceride Levels: A Retrospective Analysis

Hang Guo,1 Chunlei Ma,2 Xiaoming Wu,1 and Congqing Pan1

1NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China
2Department of Urology, Tianjin 4th Center Hospital, The Fourth Central Hospital Affiliated to Nankai University, Tianjin 300140, China

Correspondence should be addressed to Congqing Pan; cpan@tmu.edu.cn

Received 18 March 2021; Revised 19 July 2021; Accepted 31 July 2021; Published 18 August 2021

Objective. To investigate the functional status of pancreatic α and β cells in Type 2 diabetes mellitus (T2DM) patients with different plasma triglyceride (TG) levels. TG levels can be prognostic markers for T2DM.

Methods. A total of 328 patients with T2DM were divided into three groups according to different TG levels: the TGL group: TG < 1.7 mmol/L; TGM group: 1.7 mmol/L ≤ TG < 2.3 mmol/L; and TGH group: TG ≥ 2.3 mmol/L. An oral glucose tolerance test (OGTT), insulin release test, and glucagon release test were performed in each patient. The changes of glucagon, glucagon/insulin ratio, early insulin secretion index (ΔI30/ΔG30), and area under the insulin curve (AUCI) were compared among each group. Also, the correlations between glucagon and pancreatic β-cell function, glycosylated hemoglobin (HbA1c), and other indices were analyzed.

Results. With the increase of TG, the fasting and postprandial glucagon levels, the glucagon/insulin ratio, and the area under the glucagon curve (AUC G) presented an increasing trend. The homeostasis model assessment of insulin resistance (HOMA–IR) of the TGH group was significantly increased compared to the TGL and TGM groups. In addition to the increase in TG levels, the insulin sensitivity index (ISI), homeostasis model assessment for β-cell function index (HOMA-β), ΔI30/ΔG30, and AUCI displayed a reducing trend. Glucagon was negatively correlated with ΔI30/ΔG30, high-density lipoprotein (HDL), HOMA-β, body mass index (BMI), ISI, and AUCI (P < 0.05) and positively correlated with fasting blood glucose (FPG), AUCG, HOMA-IR, HbA1c, duration, TG, low-density lipoprotein (LDL), and total cholesterol (TC) (P < 0.05). Conclusion. Hypertriglyceridemia aggravated the dysfunction of pancreatic α cells and β cells. A reasonable control of the TG level makes it easier for blood glucose to reach the standard.

1. Background

Diabetes has become a global chronic noninfectious disease and a public health problem of worldwide concern [1]. The prevalence of T2DM is increasing year by year. The number of people with diabetes worldwide was estimated at almost 400 million in 2013 and is projected to increase approximately up to 600 million by 2035 [2].

In 2017, the prevalence of diabetes in China was 11.2%, making it the country with the largest number of diabetes patients [3]. As we all know, the complications of diabetes will involve multiple organs of the body and increase the risk of death. Diabetes not only reduces the quality of life of patients but also causes huge economic burden. As a result, the country’s medical resources are consumed greatly, making diabetes a huge burden for people all over the world [4].

Insulin resistance (IR) and impaired secretion of pancreatic β cells are the main pathophysiological mechanisms of T2DM [5]. Unger et al. put forward the “bihormonal theory,” which believed that not only abnormal function of pancreatic islet β cells but also abnormal function of α cells existed in diabetic patients and insulin resistance/lack and absolute/relative increase of glucagon jointly lead to diabetes.
Glycemic balance is regulated by the glucagon secreted by pancreatic α cells and insulin secreted by pancreatic β cells [7]. In recent years, the effects of glucagon on T2DM have attracted much attention from medical researchers [8].

Previous studies have found that T2DM is associated with abnormalities in lipid metabolism such as high fasting and postprandial blood levels of TG, high concentrations of nonesterified fatty acids, and low HDL concentrations [9]. In addition, a study has reported that hyperlipidemia can increase glucagon in patients with T2DM [10]. However, the relationship between blood lipid levels and the function of pancreatic α and β cells has been rarely studied. This study retrospectively analyzed the functional changes occurring in pancreatic α and β cells in T2DM patients with different plasma TG levels.

2. Participants and Methods

2.1. Participants. A total of 328 patients with T2DM admitted to Tianjin Medical University Chu Hsien-I Memorial Hospital between August 2018 and August 2020 were enrolled for the study. The study was approved by the Ethics Committee of Chu Hsien-I Memorial Hospital of Tianjin Medical University (No. DXBYYhMEC2020-35). This patient group included 168 males and 160 females with an average age of 54.9 ± 10.4 years. T2DM was diagnosed according to the diagnostic criteria laid by the World Health Organization (1999): (FBG ≥ 7.0 mmol/L and 2-hour postprandial blood glucose (2hPBG) ≥ 11.1 mmol/L). The enrolled patients were devoid of using lipid-regulating drugs or insulin preparations from six months prior to hospitalization. The patients were also inhibited from insulin secretagogues three days before the OGTT test.

2.1.1. Exclusion Criteria. Patients suffering from severe liver and kidney dysfunction, tumor, anemia, acute cardiovascular and cerebrovascular events, acute and chronic inflammation, stress state, ketosis or hypertonic coma, gestational diabetes, secondary diabetes, and other endocrine, metabolic diseases were excluded from the study.

2.1.2. Grouping. According to the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2010), the subjects were divided into three groups according to different TG levels: the TGL group: TG < 1.7 mmol/L; TGM group: 1.7 mmol/L ≤ TG < 2.3 mmol/L; and TGH group: TG ≥ 2.3 mmol/L.

2.2. Methods

2.2.1. Sampling Strategy. The venous blood was collected from the peripheral forearm of the enrolled patients after an overnight fast of 8–12 hours. TC, TG, HDL, LDL, liver, kidney function tests, and other biochemical indices were measured using the Hitachi 7180 automatic biochemical analyzer. HBA1c was determined by high-pressure liquid chromatography. An OGTT, insulin release test, and glucagon release test were performed. Patients were inhibited from using insulin secretagogue three day before the blood draw. 75 g glucose was administered orally after an overnight fast of 12 hours. Venous blood from the forearm was collected at 0, 30, 60, 120, and 180 mins, respectively, to evaluate the FBG and 2hPBG, insulin and glucagon levels. The glucose oxidase method was used to assess glucose levels. Insulin was measured by electrochemical luminescence (Roche, Germany), and glucagon was measured by non-equilibrium radioimmunity.

2.2.2. Indicators and Measurements. The area under the curve of insulin and area under the curve of glucagon were calculated using the following formula: $\text{AUCI} = 15 \times \text{fasting insulin level} + 30 \times (\text{insulin level at } 30 \text{ mins} + \text{insulin level at } 180 \text{ mins}) + 45 \times \text{insulin level at } 60 \text{ mins} + 60 \times \text{insulin level at } 120 \text{ mins} + 45 \times \text{glucagon level at } 60 \text{ mins} + 60 \times \text{glucagon level at } 120 \text{ mins}$.

Homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate IR, and the least significant difference (LSD) test. Pearson correlation analysis was used to analyze the correlation between glucagon and other parameters. $P < 0.05$ was considered statistically significant.

3. Results

3.1. Comparison of Patients’ General Information. There were no significant differences in age, gender composition, course of the disease, BMI, systolic blood pressure, diastolic blood pressure, and hemoglobin among the three groups. HbA1c, LDL, and FPG levels of the TGH group were significantly higher than those of the TGL group and TGM group. The high-density lipoprotein cholesterol was significantly increased in the TGM and TGH groups ($P < 0.05$) compared to the TGL group. A significant difference ($P < 0.05$) was observed for TC among the three groups (Table 1).

3.2. Glucagon Levels (in Fasting State and after Glucose Load) and Glucagon/Insulin Ratio in Patients with Different TG Levels. With the increase in TG levels, the three groups’
Table 1: Comparison of clinical data among patients with different TG levels.

|                | TGL (n = 114) | TGM (n = 101) | TGH (n = 113) | p value |
|----------------|---------------|---------------|---------------|---------|
| Age (year)     | 55.1 ± 9.8    | 54.0 ± 9.8    | 53.9 ± 10.1   | >0.05   |
| Female (n)     | 45            | 36            | 41            | >0.05   |
| Duration (year)| 8.6 ± 2.0     | 8.4 ± 2.4     | 7.9 ± 2.2     | >0.05   |
| BMI (kg/m²)    | 28.0 ± 2.8    | 27.1 ± 3.2    | 28.6 ± 2.2    | >0.05   |
| FPG (mmol/L)   | 7.4 ± 1.5     | 7.5 ± 1.9     | 7.9 ± 1.7*    | <0.05   |
| SBP (mmHg)     | 131.7 ± 18.0  | 131.2 ± 16.4  | 131.4 ± 16.2  | >0.05   |
| DBP (mmHg)     | 77.9 ± 9.0    | 77.2 ± 12.0   | 79.4 ± 10.5   | >0.05   |
| TC (mmol/L)    | 4.9 ± 0.9     | 5.2 ± 1.1*    | 5.5 ± 1.4*    | <0.05   |
| HDL (mmol/L)   | 1.4 ± 0.4     | 1.3 ± 0.3*    | 1.3 ± 0.3*    | <0.05   |
| LDL (mmol/L)   | 3.0 ± 0.7     | 3.3 ± 0.9     | 3.7 ± 1.0*    | <0.05   |
| HbA1c (%)      | 8.3 ± 2.4     | 8.2 ± 1.8     | 8.6 ± 2.6*    | <0.05   |
| HGB (g/L)      | 145.4 ± 16.1  | 144.0 ± 20.2  | 143.2 ± 16.6  | >0.05   |

TG: TG < 1.7 mmol/L; TGM: TG 1.7 ≤ TG < 2.3 mmol/L; TGH: TG ≥ 2.3 mmol/L; BMI (kg/m²): body mass index; TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SBP: systolic blood pressure; DBP: diastolic blood pressure; *P < 0.05 versus TGL; #P < 0.05 versus TCM.

4. Discussion

The elevation of blood glucose levels in T2DM patients is caused by the secretory dysfunction of pancreatic α and β cells [11]. Consequently, the impaired insulin secretion and excessive glucagon secretion leads to an unusual rise in glucagon/insulin ratio [12]. This condition aggravates hyperglycemia. Research by Cook et al. reported that greater than 50% of T2DM patients in the United States suffered comorbidity with varying degrees of dyslipidemia [13]. Furthermore, the CCMR-3B study performed in China involving more than 20,000 T2DM patients from 107 hospitals across the country revealed that about 42% of them were associated with dyslipidemia [14].

The prevention and treatment of dyslipidemia in diabetic patients have become a trending topic of recent research with evidence of a high prevalence of dyslipidemia [15]. The characteristic pathological features of T2DM include insulin resistance and impaired insulin secretion [16]. It has been found that the disorder in lipid metabolism can aggravate IR in T2DM patients and lipid toxicity can aggravate the functional decline of pancreatic β cells [17]. The current study results showed that the increase of plasma TG level caused an increasing trend in the insulin resistance index of pancreatic β cells, while the ISI showed a decreasing trend in T2DM patients. Simultaneously, the HOMA-β and early-phase insulin secretion index were significantly decreased, which was consistent with the results of previous studies. In hypertriglyceridemia, the TG and free fatty acids are deposited in nonadipose tissue, resulting in reduced insulin and IR biological effects. Under pathological conditions, TG and free fatty acids can be deposited in pancreatic islet tissues and directly damage pancreatic β cells, leading to insulin secretion disorder [18].

This study focused on the effect of TG level on the function of pancreatic α and β cells. In recent years, it has been found that glucagon secreted by pancreatic α cells also plays a vital role in the development and T2DM progression [19]. In this study, T2DM patients were grouped according to different TG levels. The results indicated that the increase in plasma TG levels increased the patients’ glucagon levels and AUCG. This indicated that the higher TG levels induced...
the secretion of glucagon in pancreatic α cells. It was considered that this might be related to the dysfunction of pancreatic α cells in these patients. In hypertriglyceridemia, free fatty acids lead to high glucagon secretion and increase TG accumulation and free fatty acids in pancreatic α cells. It has been speculated that continuous exposure to free fatty acids may reduce AMP-activated kinase protein activity and increase the accumulation of TG, leading to changes in the

**Figure 1:** Glucagon and glucagon/insulin before and after OGTT among patients with different HbA1c. TGL: TG < 1.7 mmol/L; TGM: TGM 1.7 ≤ TG < 2.3 mmol/L; and TGH: TG ≥ 2.3 mmol/L. *P < 0.05 versus TCL; #P < 0.05 versus TCM.

**Figure 2:** Islet β-cell function and AUCG among patients with different HbA1c levels. TGL: TG < 1.7 mmol/L; TGM: TGM 1.7 ≤ TG < 2.3 mmol/L; and TGH: TG ≥ 2.3 mmol/L. AUCG: area under the curve of glucose; ΔI30/ΔG30: ratio of insulin increment and glucose increment 30 min after glucose load; AUCI: area under the curve of insulin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostasis model assessment of insulin resistance index; and ISI: insulin sensitivity index. *P < 0.05 versus TCL; #P < 0.05 versus TCM.
insulin signal of pancreatic α cells and excessive secretion of glucagon [20]. In addition, it has been reported that pancreatic α-cell dysfunction may be mediated by the accumulation of TG-rich lipoproteins [21, 22]. Due to poor activation of GABA-A receptors of pancreatic α cells, these lipoproteins can interfere with glucagon secretion [23].

In addition to the direct effects mentioned above, the effect of blood lipids on glucagon secretion may have indirect effects. In T2DM patients, the high glucose inhibition effect can directly lead to a high secretion state of glucagon, further aggravating blood glucose disorder, forming a vicious cycle of mutual promotion of blood glucose, blood lipids, and glucagon.

The glucagon/insulin ratio is an important factor in determining blood glucose concentration. Due to impaired insulin secretion and excessive glucagon secretion in T2DM patients, the glucagon/insulin ratio is abnormally increased, thus exacerbating the hyperglycemia [24]. In this study, it was found that the glucagon/insulin ratio showed an overall increasing trend as the TG level increases in the fasting state and at each time point after the glucose load [25]. The TGH group showed consistent and significantly higher levels than TGM and TGL groups at the same time points. In hypertriglyceridemia, increased plasma free fatty acid levels lead to IR and pancreatic β-cell secretion deficiency, resulting in decreased insulin levels. Furthermore, it also affects the pancreatic α-cell function and leads to glucagon hypersecretion, resulting in increased glucagon/insulin ratio [20].

The medical records collected in this study belonged to Tianjin, China. The patient population may not represent the whole T2DM patient population.

5. Conclusions

From the present study, it can be concluded that when treating T2DM, monitoring the plasma TG levels is equally important as that of blood glucose levels. Reasonable control of the TG level is conducive to regulating the glucagon and insulin ratio to achieve a more effective standard blood glucose control.

Abbreviations

| Tg: Plasma triglyceride | OGTT: Oral glucose tolerance test | AUCg: Area under the glucose curve | HbA1c: Glycosylated hemoglobin | AUCg: Area under the glucagon curve |
|------------------------|----------------------------------|-----------------------------|-----------------|-----------------------------|

Table 2: Correlation analysis between glucagon and related parameters.

| FBG | AUCg | HOMA-IR | HbA1c | ΔI30/G30 | Duration | HDL | HOMA-β | BMI | ISI | TG | AUCg | LDL | TC |
|-----|------|---------|-------|---------|----------|-----|--------|-----|-----|----|------|-----|-----|
|     | 0.545 | 0.476 | 0.325 | 0.273 | −0.229 | 0.193 | −0.165 | −0.153 | −0.151 | −0.146 | 0.141 | −0.136 | 0.111 | 0.066 |
| r   | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
| p   | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 |

FBG: Fasting plasma glucose; AUCg: area under the curve of glucose; HOMA-IR: homeostasis model assessment of insulin resistance index; HbA1c: glycosylated hemoglobin; ΔI30/G30: ratio of insulin increment and glucose increment 30 min after glucose load; HOMA-β: homeostasis model assessment of β-cell function; BMI: body mass index; ISI: insulin sensitivity index; AUCg: area under the curve of glucagon; duration: duration of diabetes. TGL: TG < 2.3 mmol/L; TGH: TG > 2.3 mmol/L. AUCg: area under the curve of glucagon; ΔI30/G30: ratio of insulin increment and glucose increment 30 min after glucose load; AUCg: area under the curve of insulin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostasis model assessment of insulin resistance index; ISI: insulin sensitivity index.

Data Availability

All data are freely available for scientific purpose.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All the authors contributed significantly to the manuscript. HG analyzed and interpreted the data and drafted the manuscript. CM significantly revised the draft, interpreted the data, and involved in data analyses. XW conducted the study, collected the information, and participated in data interpretation. CP is the PI of the project, who designed the study and critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank the participants for participating in the study and the medical staff for collecting information and blood sample. This work was supported by the Tianjin Health Commission Science and Technology Talent Cultivation Project (KJ20022).

References

[1] S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 diabetes,” Lancet, vol. 389, no. 10085, pp. 2239–2251, 2010.
[2] N. G. Forouhi and N. J. Wareham, “Epidemiology of diabetes,” Medicine, vol. 42, no. 12, pp. 698–702, 2014.
[3] C. Hu and W. Jia, “Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication,” *Diabetes*, vol. 67, no. 1, pp. 3–11, 2018.

[4] P. Zimmet, K. G. Alberti, D. J. Magliano, and P. H. Bennett, “Diabetes mellitus statistics on prevalence and mortality: facts and fallacies,” *Nature Reviews Endocrinology*, vol. 12, no. 10, pp. 616–622, 2016.

[5] M. Kasuga, “Insulin resistance and pancreatic cell failure,” *Journal of Clinical Investigation*, vol. 116, no. 7, pp. 1756–1760, 2006.

[6] R. H. Unger, “Role of glucagon in the pathogenesis of diabetes: the status of the controversy,” *Metabolism*, vol. 27, no. 11, pp. 1691–1709, 1978.

[7] J. E. Campbell and C. B. Newgard, “Mechanisms controlling pancreatic islet cell function in insulin secretion,” *Nature Reviews Molecular Cell Biology*, vol. 22, no. 2, pp. 142–158, 2021.

[8] A. Lund, J. I. Bagger, M. Christensen, F. K. Knop, and T. Vilsbøll, “Glucagon and type 2 diabetes: the return of the alpha cell,” *Current Diabetes Reports*, vol. 14, no. 12, p. 555, 2014.

[9] S. Pastromas, A. B. Terzi, D. Tousoulis, and S. Koulouris, “Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus,” *International Journal of Cardiology*, vol. 126, no. 1, pp. 3–12, 2008.

[10] I. Pozuelo-Sanchez, A. Villasanta-Gonzalez, J. F. Alcala-Diaz et al., “Postprandial lipemia modulates pancreatic alpha-cell function in the prediction of type 2 diabetes development: the CORDIOPREV study,” *Journal of Agricultural and Food Chemistry*, vol. 68, no. 5, pp. 1266–1275, 2020.

[11] B. Göke, “Islet cell function: α and β cells-partners towards normoglycaemia,” *International Journal of Clinical Practice*, vol. 62, no. 159, pp. 2–7, 2008.

[12] H.-Z. Ren, M.-Y. Zheng, C.-Y. Shan et al., “Relationship between circadian blood pressure variability and function of islet α and β cell in type 2 diabetes with dysomnia,” *Journal of Diabetology and Its Complications*, vol. 29, no. 5, pp. 675–678, 2015.

[13] C. B. Cook, D. M. Erdman, G. J. Ryan et al., “The pattern of dyslipidemia among urban African-Americans with type 2 diabetes,” *Diabetes Care*, vol. 23, no. 3, pp. 319–324, 2000.

[14] L. Ji, D. Hu, C. Pan et al., “Betes patients,” *The American Journal of Medicine*, vol. 126, no. 10, pp. 925.e911–925.e922, 2013.

[15] R. Bitzur, H. Cohen, Y. Kamari, A. Shaish, and D. Harats, “Triglycerides and HDL cholesterol: stars or second leads in diabetes?” *Diabetes Care*, vol. 32, no. 2, pp. S373–S377, 2009.

[16] J. Yan, D. Peng, F. Jiang et al., “Impaired pancreatic beta cell compensatory function is the main cause of type 2 diabetes in individuals with high genetic risk: a 9 year prospective cohort study in the Chinese population,” *Diabetologia*, vol. 59, no. 7, pp. 1458–1462, 2016.

[17] M. Prentki, M.-L. Peyot, P. Masiello, and S. R. M. Madiraju, “Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic β-cell,” *Diabetes*, vol. 69, no. 3, pp. 279–290, 2020.

[18] N. Stefan and H.-U. Häring, “Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans,” *Nature Medicine*, vol. 19, no. 4, pp. 394–395, 2013.

[19] D. D’Alessio, “The role of dysregulated glucagon secretion in type 2 diabetes,” *Diabetes, Obesity and Metabolism*, vol. 13, no. Suppl 1, pp. 126–132, 2011.

[20] H. Manell, H. Kristinsson, J. Kullberg et al., “Hyper-glucagonemia in youth is associated with high plasma free fatty acids, visceral adiposity, and impaired glucose tolerance,” *Pediatric Diabetes*, vol. 20, no. 7, pp. 880–891, 2019.

[21] J. Hong, P. B. Jeppesen, I. Nordentoft, and K. Hermansen, “Fatty acid-induced effect on glucagon secretion is mediated via fatty acid oxidation,” *Diabetes/Metabolism Research and Reviews*, vol. 23, no. 3, pp. 202–210, 2017.

[22] H. Kristinsson, E. Sargsyan, H. Manell, D. M. Smith, S. O. Göpel, and P. Bergsten, “Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion,” *Scientific Reports*, vol. 7, no. 1, p. 4657, 2017.

[23] A. Niederwanger, C. Ciardi, T. Tatarczyk et al., “Postprandial lipemia induces pancreatic α cell dysfunction characteristic of type 2 diabetes: studies in healthy subjects, mouse pancreatic islets, and cultured pancreatic α cells,” *American Journal of Clinical Nutrition*, vol. 100, no. 5, pp. 1222–1231, 2014.

[24] M. Lee, M. Kim, J. S. Park et al., “Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients,” *The Korean Journal of Internal Medicine*, vol. 34, no. 5, pp. 1068–1077, 2019.

[25] M. Seghieri, D. Tricó, and A. Natali, “The impact of triglycerides on glucose tolerance: lipotoxicity revisited,” *Diabetes and Metabolism*, vol. 43, no. 4, pp. 314–322, 2017.